Clinical trials: Non-small Cell Lung Cancer (NSCLC), open to volunteers
NSCLC, Stage III, Locally Advanced Lung Carcinoma
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
- Trial name
- Microdurva (NCT04680377)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Jun Zhang, MD, PhD
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Pulmonary Function Assessment, Disease Free Survival
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.
- Conditions
- Pulmonary Function Assessment, Disease Free Survival, NSCLC, Stage I
- Trial name
- NCT06404164
- Testing
- Wedge resection under watershed analysis method
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Local Advanced or Metastatic NSCLC
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in…
- Trial name
- NCT06380348
- Testing
- JMT101 Injection, Osimertinib tablet, Cisplatin injection
- Volunteers
- 398 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lung Cancer, NSCLC
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IV
- Trial name
- TUMORIN (NCT05332925)
- Testing
- Standard of care immune checkpoint inhbitors
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jun Zhang, MD, PhD
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Oncology, NSCLC Stage IV
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer.
- Conditions
- Oncology, NSCLC Stage IV, NSCLC, Stage III
- Trial name
- LUNGVAC (NCT05344209)
- Testing
- UV1, Sagramostim, Anti-PD-1/PD-L1 treatment
- Where
- Norway
- Volunteers
- 138 people
- Sponsor
- Vestre Viken Hospital Trust
NSCLC, Cancer
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally…
- Conditions
- NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT05550961
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NSCLC, BRAF V600E Mutation
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
- Conditions
- NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- NCT05988697
- Testing
- Combind asprin with Trametinib and Dabrafenib
- Volunteers
- 36 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Locally Advanced or Metastatic NSCLC
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic…
- Trial name
- NCT05990127
- Testing
- AK104, Tislelizumab, carboplatin
- Where
- 62 sites in China
- Volunteers
- 642 people
- Sponsor
- Akeso
Non-Small-Cell Lung Cancer (NSCLC), Brain Metastasis
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
Background. During the clinical course of patients with locoregionally advanced non-small-cell lung cancer (LA-NSCLC) who have undergone aggressive treatment, brain metastasis (BM) is a frequent seen pattern of disease relapse…
- Trial name
- NCT02448992
- Testing
- hippocampal-sparing WBRT
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Small Cell Lung Cancer (NSCLC)
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with…
- Trial name
- NCT05271916
- Testing
- Dacomitinib+Anlotinib, Dacomitinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT05767892
- Testing
- YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
- Where
- 52 sites in China
- Volunteers
- 350 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
NSCLC, Stage I
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant…
- Trial name
- NCT05686434
- Testing
- Osimertinib
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC Stage IV, HIV
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID…
- Conditions
- NSCLC Stage IV, HIV, HBV, HCV
- Trial name
- LUNGVIR (NCT05597800)
- Testing
- Nivolumab and Ipilimumab
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Universita di Verona
Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Patient's Whole Process Follow-up Management(HOPE-1)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
- Trial name
- HOPE-1 (NCT05339568)
- Testing
- Patients' whole process follow-up and management platform
- Where
- China
- Volunteers
- 1,268 people
- Sponsor
- Qianfoshan Hospital
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
NSCLC, EGFR Gene Mutation
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
This study involves patients with EGFR-mutated NSCLC and asymptomatic brain metastases. This is an open-label, randomized study, comparing the continuation of Osimertinib treatment alone to Osimertinib treatment combined with…
- Conditions
- NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05033691
- Testing
- Stereotactic surgery
- Where
- Israel
- Volunteers
- 162 people
- Sponsor
- Hadassah Medical Organization